<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">lvrach</journal-id><journal-title-group><journal-title xml:lang="ru">Лечащий Врач</journal-title><trans-title-group xml:lang="en"><trans-title>Lechaschi Vrach</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-5175</issn><issn pub-type="epub">2687-1181</issn><publisher><publisher-name>ООО «Издательство "Открытые системы"»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51793/OS.2022.25.12.008</article-id><article-id custom-type="elpub" pub-id-type="custom">lvrach-1004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭНДОКРИНОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ENDOCRINOLOGY</subject></subj-group></article-categories><title-group><article-title>К вопросу о фармакологической коррекции показателей углеводного и липидного обменов у пациентов с метаболическим синдромом</article-title><trans-title-group xml:lang="en"><trans-title>An addition to pharmacological correction of carbohydrate and lipid metabolism in patients with metabolic syndrome</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2164-3537</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скворцов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Skvortsov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Скворцов Всеволод Владимирович, д. м. н., профессор кафедры внутренних болезней</p><p>400131, Волгоград, пл. Павших Борцов, 1</p></bio><bio xml:lang="en"><p>Vsevolod V. Skvortsov, Dr. of Sci. (Med.), Professor of the Department of Internal Diseases</p><p>1 Pavshikh Bortsov Square, Volgograd, 400131</p></bio><email xlink:type="simple">vskvortsov1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6433-9068</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малякина</surname><given-names>Э. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Malyakina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Малякина Эллина Альбертовна, ординатор</p><p>117198, Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>Ellina A. Malyakina, resident</p><p>6 Miklukho-Maklaya str., Moscow, 117198</p></bio><email xlink:type="simple">golieva133@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1128-2678</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малякин</surname><given-names>Г. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Malyakin</surname><given-names>G. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Малякин Георгий Ильич, ординатор</p><p>119991, Россия, Москва, ул. Трубецкая, 8, стр. 2</p></bio><bio xml:lang="en"><p>Grigoriy I. Malyakin, resident</p><p>8 b. 2 Trubetskaya str., Moscow, 119991</p></bio><email xlink:type="simple">manuljke@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования Волгоградский государственный медицинский университет Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Educational Institution of Higher Education Volgograd State Medical University of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования Российский университет дружбы народов</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Educational Institution of Higher Education Peoples' Friendship University of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И. М. Сеченова Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Autonomous Educational Institution of Higher Education I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>03</day><month>01</month><year>2023</year></pub-date><volume>0</volume><issue>12</issue><fpage>44</fpage><lpage>50</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Скворцов В.В., Малякина Э.А., Малякин Г.И., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Скворцов В.В., Малякина Э.А., Малякин Г.И.</copyright-holder><copyright-holder xml:lang="en">Skvortsov V.V., Malyakina E.A., Malyakin G.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.lvrach.ru/jour/article/view/1004">https://journal.lvrach.ru/jour/article/view/1004</self-uri><abstract><p>Ожирение является причиной многих заболеваний, а также психоэмоциональных, социальных и экономических проблем. Факторами, предрасполагающими к развитию метаболического синдрома, являются генетическая предрасположенность, пожилой возраст, постменопаузальный статус у женщин, поведенческие моменты (малоподвижный образ жизни, преобладание жирной пищи в рационе), низкий социально-экономический статус. Метаболический синдром характеризуется увеличением массы висцерального жира, снижением чувствительности периферических тканей к инсулину и гиперинсулинемией, которые вызывают развитие нарушений углеводного, липидного, пуринового обменов и артериальной гипертонии. Наличие метаболического синдрома приводит к повышенному риску развития сахарного диабета 2 типа и сердечно-сосудистых заболеваний. Риск смертности, связанной с сердечно-сосудистыми заболеваниями, также выше у тех, у кого диагностирован данный синдром. Добавки, содержащие клетчатку, могут стать удобной и экономичной альтернативой для увеличения содержания этого элемента питания в рационе без необходимости других серьезных модификаций рациона. Псиллиум тщательно исследован, так как он содержится во многих популярных безрецептурных слабительных средствах по всему миру. Многочисленные исследования указывают на улучшение контроля гликемии и HbA1c у людей с диабетом 1 или 2 типа, которые потребляли больше пищевых волокон. По данным Управления по надзору за качеством пищевых продуктов и лекарственных средств США (Food and Drugs Administration of the United States), потребление 1,78 г псиллиума на порцию (4 порции в день) способствует улучшению уровня липидов, снижению сердечно-сосудистых факторов риска. Исследования не показали каких-либо улучшений артериального давления или сосудистой функции у лиц с избыточной массой тела и ожирением при приеме пищевых волокон псиллиума в течение 12 недель вмешательства. Рандомизированное клиническое исследование 2016 года показало статистически значимое снижение веса, индекса массы тела и окружности талии и бедер у пациентов с сахарным диабетом 2 типа. В Российской Федерации псиллиум также представлен в виде лекарственного препарата.</p></abstract><trans-abstract xml:lang="en"><p>Obesity is the cause of many diseases, as well as psycho-emotional, social and economic problems. Factors predisposing to the development of metabolic syndrome are genetic predisposition, advanced age, postmenopausal status in women, behavioral factors (a sedentary lifestyle, the predominance of fatty foods in the diet), and low socioeconomic status. Metabolic syndrome is characterized by an increase in the mass of visceral fat, a decrease in the sensitivity of peripheral tissues to insulin and hyperinsulinemia, which cause the development of disorders of carbohydrate, lipid, purine metabolism and arterial hypertension. The presence of metabolic syndrome leads to an increased risk of developing type 2 diabetes and cardiovascular disease. The risk of mortality associated with cardiovascular disease is also higher in those diagnosed with this syndrome. Fiber supplements can be a convenient and cost-effective alternative to increase fiber content in the diet without the need for other major dietary modifications. Psyllium has been extensively researched as it is found in many popular over-the-counter laxatives around the world. Numerous studies point to improved glycemic and HbA1c control in people with type 1 or type 2 diabetes who consumed more dietary fiber. According to the Управление по надзору за качеством пищевых продуктов и лекарственных средств Food and Drugs Administration of the United States, consumption of 1.78 g of psyllium per serving (4 servings per day) improves lipid levels, reduces cardiovascular risk factors. Studies have not shown any improvement in BP or vascular function in overweight and obese individuals with psyllium fiber supplementation during the 12 weeks of intervention. A 2016 randomized clinical trial showed statistically significant reductions in weight, body mass index, and waist and hip circumference in patients with type 2 diabetes. In the Russian Federation, psyllium is also presented in the form of the drug.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>метаболический синдром</kwd><kwd>ожирение</kwd><kwd>избыточный вес</kwd><kwd>пищевые волокна</kwd><kwd>псиллиум</kwd><kwd>липопротеины низкой плотности</kwd><kwd>гипергликемия</kwd><kwd>сахарный диабет</kwd><kwd>триглицериды</kwd><kwd>мукофальк</kwd></kwd-group><kwd-group xml:lang="en"><kwd>metabolic syndrome</kwd><kwd>obesity</kwd><kwd>overweight</kwd><kwd>dietary fiber</kwd><kwd>psyllium</kwd><kwd>low-density lipoproteins</kwd><kwd>hyperglycemia</kwd><kwd>diabetes mellitus</kwd><kwd>triglycerides</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organisation. World Health Statistics 2014. Geneva, Switzerland: WHO; 2014.</mixed-citation><mixed-citation xml:lang="en">World Health Organisation. World Health Statistics 2014. Geneva, Switzerland: WHO; 2014.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wilborn C., Beckham J., Campbell B., et al. Obesity: prevalence, theories, medical consequences, management, and research directions // J Int Soc Sports Nutr. 2005; 2 (2): 4-31. Published 2005 Dec 9. DOI: 10.1186/1550-2783-2-2-4.</mixed-citation><mixed-citation xml:lang="en">Wilborn C., Beckham J., Campbell B., et al. Obesity: prevalence, theories, medical consequences, management, and research directions // J Int Soc Sports Nutr. 2005; 2 (2): 4-31. Published 2005 Dec 9. DOI: 10.1186/1550-2783-2-2-4.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Belgium: IDF; 2006.</mixed-citation><mixed-citation xml:lang="en">International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Belgium: IDF; 2006.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">International Diabetes Federation. Criteria of metabolic syndrome in children and adolescents. Belgium: IDF; 2015.</mixed-citation><mixed-citation xml:lang="en">International Diabetes Federation. Criteria of metabolic syndrome in children and adolescents. Belgium: IDF; 2015.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu L., Spence C., Yang J. W., Ma G. X. The IDF Definition Is Better Suited for Screening Metabolic Syndrome and Estimating Risks of Diabetes in Asian American Adults: Evidence from NHANES 2011-2016 // J Clin Med. 2020; 9 (12): 3871. Published 2020 Nov 28. DOI: 10.3390/jcm9123871.</mixed-citation><mixed-citation xml:lang="en">Zhu L., Spence C., Yang J. W., Ma G. X. The IDF Definition Is Better Suited for Screening Metabolic Syndrome and Estimating Risks of Diabetes in Asian American Adults: Evidence from NHANES 2011-2016 // J Clin Med. 2020; 9 (12): 3871. Published 2020 Nov 28. DOI: 10.3390/jcm9123871.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gurka M. J., Guo Y., Filipp S. L., DeBoer M. D. Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes // Cardiovasc Diabetol. 2018; 17 (1): 17. Published 2018 Jan 19. DOI: 10.1186/s12933-017-0647-y.</mixed-citation><mixed-citation xml:lang="en">Gurka M. J., Guo Y., Filipp S. L., DeBoer M. D. Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes // Cardiovasc Diabetol. 2018; 17 (1): 17. Published 2018 Jan 19. DOI: 10.1186/s12933-017-0647-y.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Рекомендации по ведению больных с метаболическим синдромом. Министерство здравоохранения Российской Федерации, Москва, 2013.</mixed-citation><mixed-citation xml:lang="en">Recommendations for the management of patients with metabolic syndrome. Ministerstvo zdravookhraneniya Rossiyskoi Federatsii, Moskva, 2013 g.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bovolini A., Garcia J., Andrade M. A., Duarte J. A. Metabolic Syndrome Pathophysiology and Predisposing Factors // Int J Sports Med. 2021; 42 (3): 199-214. DOI: 10.1055/a-1263-0898.</mixed-citation><mixed-citation xml:lang="en">Bovolini A., Garcia J., Andrade M. A., Duarte J. A. Metabolic Syndrome Pathophysiology and Predisposing Factors // Int J Sports Med. 2021; 42 (3): 199-214. DOI: 10.1055/a-1263-0898.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Riccioni G., Sblendorio V., Gemello E., Di Bello B., Scotti L., Cusenza S., et al. Dietary fibers and cardiometabolic diseases // International Journal of Molecular Sciences. 2012; 13: 1524-1540.</mixed-citation><mixed-citation xml:lang="en">Riccioni G., Sblendorio V., Gemello E., Di Bello B., Scotti L., Cusenza S., et al. Dietary fibers and cardiometabolic diseases // International Journal of Molecular Sciences. 2012; 13: 1524-1540.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hartley L., May M. D., Loveman E., Colquitt J. L., K. R. Dietary fibre for the primary prevention of cardiovascular disease // Cochrane Database of Systematic Reviews. 2016; 1.</mixed-citation><mixed-citation xml:lang="en">Hartley L., May M. D., Loveman E., Colquitt J. L., K. R. Dietary fibre for the primary prevention of cardiovascular disease // Cochrane Database of Systematic Reviews. 2016; 1.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">McKeown N. M., Fahey G. C. Jr., Slavin J., van der Kamp J. W. Fibre intake for optimal health: how can healthcare professionals support people to reach dietary recommendations? // BMJ. 2022; 378: e054370. Published 2022 Jul 20. DOI: 10.1136/bmj-2020-054370.</mixed-citation><mixed-citation xml:lang="en">McKeown N. M., Fahey G. C. Jr., Slavin J., van der Kamp J. W. Fibre intake for optimal health: how can healthcare professionals support people to reach dietary recommendations? // BMJ. 2022; 378: e054370. Published 2022 Jul 20. DOI: 10.1136/bmj-2020-054370.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Australian Bureau of Statistics. Australian Health Survey: Consumption of food groups from the Australian Dietary Guidelines. Canberra: Commonwealth of Australia; 2016.</mixed-citation><mixed-citation xml:lang="en">Australian Bureau of Statistics. Australian Health Survey: Consumption of food groups from the Australian Dietary Guidelines. Canberra: Commonwealth of Australia; 2016.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Gurka M. J., Guo Y., Filipp S. L., DeBoer M. D. Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes // Cardiovasc Diabetol. 2018; 17 (1): 17. Published 2018 Jan 19. DOI: 10.1186/s12933-017-0647-y.</mixed-citation><mixed-citation xml:lang="en">Gurka M. J., Guo Y., Filipp S. L., DeBoer M. D. Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes // Cardiovasc Diabetol. 2018; 17 (1): 17. Published 2018 Jan 19. DOI: 10.1186/s12933-017-0647-y.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Jane M., McKay J., Pal S. Effects of daily consumption of psyllium, oat bran and polyGlycopleX on obesity-related disease risk factors: A critical review // Nutrition. 2019; 57: 84-91. DOI: 10.1016/j.nut.2018.05.036.</mixed-citation><mixed-citation xml:lang="en">Jane M., McKay J., Pal S. Effects of daily consumption of psyllium, oat bran and polyGlycopleX on obesity-related disease risk factors: A critical review // Nutrition. 2019; 57: 84-91. DOI: 10.1016/j.nut.2018.05.036.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Phillips K. M., McGinty R. C., Couture G., Pehrsson P. R., McKillop K., Fukagawa N. K. Dietary fiber, starch, and sugars in bananas at different stages of ripeness in the retail market // PLoS One. 2021; 16 (7): e0253366. Published 2021 Jul 8. DOI: 10.1371/journal.pone.0253366.</mixed-citation><mixed-citation xml:lang="en">Phillips K. M., McGinty R. C., Couture G., Pehrsson P. R., McKillop K., Fukagawa N. K. Dietary fiber, starch, and sugars in bananas at different stages of ripeness in the retail market // PLoS One. 2021; 16 (7): e0253366. Published 2021 Jul 8. DOI: 10.1371/journal.pone.0253366.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Williams P. G. The benefits of breakfast cereal consumption: a systematic review of the evidence base // Adv Nutr. 2014; 5 (5): 636S-673S. Published 2014 Sep 15. DOI: 10.3945/an.114.006247.</mixed-citation><mixed-citation xml:lang="en">Williams P. G. The benefits of breakfast cereal consumption: a systematic review of the evidence base // Adv Nutr. 2014; 5 (5): 636S-673S. Published 2014 Sep 15. DOI: 10.3945/an.114.006247.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sec. 101.81 Health claims: Soluble fiber from certain foods and risk of coronary heart disease (CHD) Archived 2019-05-23 at the Wayback Machine U.S. Food and Drug Administration, Code of Federal Regulations Title 21.</mixed-citation><mixed-citation xml:lang="en">Sec. 101.81 Health claims: Soluble fiber from certain foods and risk of coronary heart disease (CHD) Archived 2019-05-23 at the Wayback Machine U.S. Food and Drug Administration, Code of Federal Regulations Title 21.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Qualified Health Claim for Diabetes Archived 2017-05-08 at the Wayback Machine US Food and Drug Administration (June 24, 2014).</mixed-citation><mixed-citation xml:lang="en">Qualified Health Claim for Diabetes Archived 2017-05-08 at the Wayback Machine US Food and Drug Administration (June 24, 2014).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">McRorie J. W. Psyllium Is Not Fermented in the Human Gut. Neurogastroenterol // Motil. 2015; 27: 1681-1682. DOI: 10.1111/nmo.12649.</mixed-citation><mixed-citation xml:lang="en">McRorie J. W. Psyllium Is Not Fermented in the Human Gut. Neurogastroenterol // Motil. 2015; 27: 1681-1682. DOI: 10.1111/nmo.12649.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Silva F. M., Kramer C. K., de Almeida J. C., Steemburgo T., Gross J. L., Azevedo M. J. Fiber Intake and Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review with Meta-Analysis of Randomized Controlled Trials // Nutr. Rev. 2013; 71: 790-801. DOI: 10.1111/nure.12076.</mixed-citation><mixed-citation xml:lang="en">Silva F. M., Kramer C. K., de Almeida J. C., Steemburgo T., Gross J. L., Azevedo M. J. Fiber Intake and Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review with Meta-Analysis of Randomized Controlled Trials // Nutr. Rev. 2013; 71: 790-801. DOI: 10.1111/nure.12076.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">McRae M. P. Dietary Fiber Intake and Type 2 Diabetes Mellitus: An Umbrella Review of Meta-Analyses // J. Chiropr. Med. 2018; 17: 44-53. DOI: 10.1016/j.jcm.2017.11.002.</mixed-citation><mixed-citation xml:lang="en">McRae M. P. Dietary Fiber Intake and Type 2 Diabetes Mellitus: An Umbrella Review of Meta-Analyses // J. Chiropr. Med. 2018; 17: 44-53. DOI: 10.1016/j.jcm.2017.11.002.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sandberg J. C., Björck I. M. E., Nilsson A. C. Effects of Whole Grain Rye, with and without Resistant Starch Type 2 Supplementation, on Glucose Tolerance, Gut Hormones, Inflammation and Appetite Regulation in an 11-14.5 Hour Perspective; a Randomized Controlled Study in Healthy Subjects // Nutr. J. 2017; 16: 25. DOI: 10.1186/s12937-017-0246-5.</mixed-citation><mixed-citation xml:lang="en">Sandberg J. C., Björck I. M. E., Nilsson A. C. Effects of Whole Grain Rye, with and without Resistant Starch Type 2 Supplementation, on Glucose Tolerance, Gut Hormones, Inflammation and Appetite Regulation in an 11-14.5 Hour Perspective; a Randomized Controlled Study in Healthy Subjects // Nutr. J. 2017; 16: 25. DOI: 10.1186/s12937-017-0246-5.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson S. V., Hannon B. A., An R., Holscher H. D. Effects of Isolated Soluble Fiber Supplementation on Body Weight, Glycemia, and Insulinemia in Adults with Overweight and Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials // Am. J. Clin. Nutr. 2017; 106: 1514-1528. DOI: 10.3945/ajcn.117.163246.</mixed-citation><mixed-citation xml:lang="en">Thompson S. V., Hannon B. A., An R., Holscher H. D. Effects of Isolated Soluble Fiber Supplementation on Body Weight, Glycemia, and Insulinemia in Adults with Overweight and Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials // Am. J. Clin. Nutr. 2017; 106: 1514-1528. DOI: 10.3945/ajcn.117.163246.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Pal S., Khossousi A., Binns C., Dhaliwal S., Ellis V. The effect of a fibre supplement compared to a healthy diet on body composition, lipids, glucose, insulin and other metabolic syndrome risk factors in overweight and obese individuals // Br J Nutr. 2011; 105 (1): 90-100. DOI: 10.1017/S0007114510003132.</mixed-citation><mixed-citation xml:lang="en">Pal S., Khossousi A., Binns C., Dhaliwal S., Ellis V. The effect of a fibre supplement compared to a healthy diet on body composition, lipids, glucose, insulin and other metabolic syndrome risk factors in overweight and obese individuals // Br J Nutr. 2011; 105 (1): 90-100. DOI: 10.1017/S0007114510003132.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Pal S., Radavelli-Bagatini S. Effects of psyllium on metabolic syndrome risk factors // Obes Rev. 2012; 13 (11): 1034-1047. DOI: 10.1111/j.1467-789X.2012.01020.x.</mixed-citation><mixed-citation xml:lang="en">Pal S., Radavelli-Bagatini S. Effects of psyllium on metabolic syndrome risk factors // Obes Rev. 2012; 13 (11): 1034-1047. DOI: 10.1111/j.1467-789X.2012.01020.x.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Abutair A. S., Naser I. A., Hamed A. T. Soluble fibers from psyllium improve glycemic response and body weight among diabetes type 2 patients (randomized control trial) // Nutr J. 2016; 15 (1): 86. Published 2016 Oct 12. DOI: 10.1186/s12937-016-0207-4.</mixed-citation><mixed-citation xml:lang="en">Abutair A. S., Naser I. A., Hamed A. T. Soluble fibers from psyllium improve glycemic response and body weight among diabetes type 2 patients (randomized control trial) // Nutr J. 2016; 15 (1): 86. Published 2016 Oct 12. DOI: 10.1186/s12937-016-0207-4.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Khossousi A., Binns C. W., Dhaliwal S. S., Pal S. The acute effects of psyllium on postprandial lipaemia and thermogenesis in overweight and obese men // Br J Nutr. 2008; 99 (5): 1068-1075. DOI: 10.1017/S0007114507864804.</mixed-citation><mixed-citation xml:lang="en">Khossousi A., Binns C. W., Dhaliwal S. S., Pal S. The acute effects of psyllium on postprandial lipaemia and thermogenesis in overweight and obese men // Br J Nutr. 2008; 99 (5): 1068-1075. DOI: 10.1017/S0007114507864804.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">FDA. Control of health claims in foods // Lancet. 1998; 351: 609. DOI: 10.1016/S0140-6736(98)21009-9.</mixed-citation><mixed-citation xml:lang="en">FDA. Control of health claims in foods // Lancet. 1998; 351: 609. DOI: 10.1016/S0140-6736(98)21009-9.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Jenkins D. J., Kendall C. W., Vuksan V., et al. Soluble fiber intake at a dose approved by the US Food and Drug Administration for a claim of health benefits: serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial // Am J Clin Nutr. 2002; 75 (5): 834-839. DOI: 10.1093/ajcn/75.5.834.</mixed-citation><mixed-citation xml:lang="en">Jenkins D. J., Kendall C. W., Vuksan V., et al. Soluble fiber intake at a dose approved by the US Food and Drug Administration for a claim of health benefits: serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial // Am J Clin Nutr. 2002; 75 (5): 834-839. DOI: 10.1093/ajcn/75.5.834.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Sierra M., García J. J., Fernández N., Diez M. J., Calle A. P. Therapeutic effects of psyllium in type 2 diabetic patients // Eur J Clin Nutr. 2002; 56 (9): 830-842. DOI: 10.1038/sj.ejcn.1601398.</mixed-citation><mixed-citation xml:lang="en">Sierra M., García J. J., Fernández N., Diez M. J., Calle A. P. Therapeutic effects of psyllium in type 2 diabetic patients // Eur J Clin Nutr. 2002; 56 (9): 830-842. DOI: 10.1038/sj.ejcn.1601398.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson J. W., Zettwoch N., Feldman T., Tietyen-Clark J., Oeltgen P., Bishop C. W. Cholesterol-lowering effects of psyllium hydrophilic mucilloid for hypercholesterolemic men // Arch Intern Med. 1988; 148 (2): 292-296.</mixed-citation><mixed-citation xml:lang="en">Anderson J. W., Zettwoch N., Feldman T., Tietyen-Clark J., Oeltgen P., Bishop C. W. Cholesterol-lowering effects of psyllium hydrophilic mucilloid for hypercholesterolemic men // Arch Intern Med. 1988; 148 (2): 292-296.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Jovanovski E., Yashpal S., Komishon A., et al. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials // Am J Clin Nutr. 2018; 108 (5): 922-932. DOI: 10.1093/ajcn/nqy115.</mixed-citation><mixed-citation xml:lang="en">Jovanovski E., Yashpal S., Komishon A., et al. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials // Am J Clin Nutr. 2018; 108 (5): 922-932. DOI: 10.1093/ajcn/nqy115.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Pal S., Khossousi A., Binns C., Dhaliwal S., Radavelli-Bagatini S. The effects of 12-week psyllium fibre supplementation or healthy diet on blood pressure and arterial stiffness in overweight and obese individuals // Br J Nutr. 2012; 107 (5): 725-734. DOI: 10.1017/S0007114511003497.</mixed-citation><mixed-citation xml:lang="en">Pal S., Khossousi A., Binns C., Dhaliwal S., Radavelli-Bagatini S. The effects of 12-week psyllium fibre supplementation or healthy diet on blood pressure and arterial stiffness in overweight and obese individuals // Br J Nutr. 2012; 107 (5): 725-734. DOI: 10.1017/S0007114511003497.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Abutair A. S., Naser I. A., Hamed A. T. Soluble fibers from psyllium improve glycemic response and body weight among diabetes type 2 patients (randomized control trial) // Nutr J. 2016; 15 (1): 86. DOI: 10.1186/s12937-016-0207-4. PMID: 27733151; PMCID: PMC5062871.</mixed-citation><mixed-citation xml:lang="en">Abutair A. S., Naser I. A., Hamed A. T. Soluble fibers from psyllium improve glycemic response and body weight among diabetes type 2 patients (randomized control trial) // Nutr J. 2016; 15 (1): 86. DOI: 10.1186/s12937-016-0207-4. PMID: 27733151; PMCID: PMC5062871.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Alemán A. M., Quirce S., Bombín C., Sastre J. Asma relacionada con la inhalación de Plantago ovata [Asthma related to inhalation of Plantago ovata] // Med Clin (Barc). 2001; 116 (1): 20-22.</mixed-citation><mixed-citation xml:lang="en">Alemán A. M., Quirce S., Bombín C., Sastre J. Asma relacionada con la inhalación de Plantago ovata [Asthma related to inhalation of Plantago ovata] // Med Clin (Barc). 2001; 116 (1): 20-22.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Pal S., McKay J., Ho S., Jane M., Gahler R. J., Wood S. Micronutrient status of individuals with overweight and obesity following 3 months' supplementation with PolyGlycopleX (PGX®) or psyllium: a randomized controlled trial // BMC Nutr. 2022; 8 (1): 42. Published 2022 May 3. DOI: 10.1186/s40795-022-00534-7.</mixed-citation><mixed-citation xml:lang="en">Pal S., McKay J., Ho S., Jane M., Gahler R. J., Wood S. Micronutrient status of individuals with overweight and obesity following 3 months' supplementation with PolyGlycopleX (PGX®) or psyllium: a randomized controlled trial // BMC Nutr. 2022; 8 (1): 42. Published 2022 May 3. DOI: 10.1186/s40795-022-00534-7.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Мукофальк® в клинической практике, DR. FALK PHARMA GmbH, 2014. [Mucofalk® in clinical practice, DR. FALK PHARMA GmbH, 2014]</mixed-citation><mixed-citation xml:lang="en">Мукофальк® в клинической практике, DR. FALK PHARMA GmbH, 2014. [Mucofalk® in clinical practice, DR. FALK PHARMA GmbH, 2014]</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Huwiler V. V., Schönenberger K. A., Segesser von Brunegg A., et al. Prolonged Isolated Soluble Dietary Fibre Supplementation in Overweight and Obese Patients: A Systematic Review with Meta-Analysis of Randomised Controlled Trials // Nutrients. 2022; 14 (13): 2627. Published 2022 Jun 24. DOI: 10.3390/nu14132627.</mixed-citation><mixed-citation xml:lang="en">Huwiler V. V., Schönenberger K. A., Segesser von Brunegg A., et al. Prolonged Isolated Soluble Dietary Fibre Supplementation in Overweight and Obese Patients: A Systematic Review with Meta-Analysis of Randomised Controlled Trials // Nutrients. 2022; 14 (13): 2627. Published 2022 Jun 24. DOI: 10.3390/nu14132627.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Pollet A., van Craeyveld V., van de Wiele T., Verstraete W., Delcour J. A., Courtin C. M. In vitro fermentation of arabinoxylan oligosaccharides and low molecular mass arabinoxylans with different structural properties from wheat (Triticum aestivum L.) bran and psyllium (Plantago ovata Forsk) seed husk // J Agric Food Chem. 2012; 60 (4): 946-954. DOI: 10.1021/jf203820j</mixed-citation><mixed-citation xml:lang="en">Pollet A., van Craeyveld V., van de Wiele T., Verstraete W., Delcour J. A., Courtin C. M. In vitro fermentation of arabinoxylan oligosaccharides and low molecular mass arabinoxylans with different structural properties from wheat (Triticum aestivum L.) bran and psyllium (Plantago ovata Forsk) seed husk // J Agric Food Chem. 2012; 60 (4): 946-954. DOI: 10.1021/jf203820j</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
